What are NAD+ injections?

NAD+ is a coenzyme, not a peptide. It belongs to a nucleotide coenzyme system, not the amino-acid chains called peptides. Its NAD+/NADH pair carries electrons in metabolic reactions. That is an established biological role; an advertised injection plan is a separate intervention whose outcomes require human evidence.

“Longevity” describes a broad goal and market, not a chemical family. NAD+ and the peptide sermorelin can therefore appear in one publication without being interchangeable. Grant et al.: human NAD+ IV pilot (2019) The full answer on whether NAD+ is a peptide sets out the records and how 11 seller pages label it.

The answer depends on the outcome and the formulation. A 2019 pilot study followed 11 men: eight received NAD+ by a six-hour IV infusion and three received saline. It measured changes in blood and urine metabolites over a short period. It did not measure a longer lifespan or establish the effectiveness of the at-home injection subscriptions compared here.

The small, male-only sample, biochemical endpoints and disclosed industry connections limit what can be concluded. Changes in a laboratory measurement are not the same as a demonstrated improvement in fatigue, cognition or long-term health. Grant et al.: human NAD+ IV pilot (2019)

An April 2026 preprint reports small human subcutaneous and intramuscular NAD+ groups. It reports short-term safety observations, not a dependable timeline for visible or symptom improvements. The NAD injections before-and-after evidence guide separates those findings from IV research and unpublished registry results.

There is no universal winner established by the sources in this guide. An IV infusion in a clinic, an at-home injection, a nasal product, oral NAD+ and a precursor such as NR or NMN are distinct comparisons. A result for one route or ingredient should not be presented as evidence for the others.

Our launch price board intentionally compares injection offers. The linked provider pages also advertise other formats, but we do not assign them equivalent doses, absorption or outcomes. Grant et al.: human NAD+ IV pilot (2019) Doses by route, and what each seller publishes about strength, are in the NAD+ dosage guide. Read the dedicated NAD+ nasal spray audit or NAD+ injection vs IV comparison, then see the injection provider comparison.

Compounded injections raise product-quality questions as well as questions about whether treatment is appropriate for an individual. FDA does not approve or review compounded drugs before marketing for safety, effectiveness and quality. Contamination and incorrect ingredient amounts can create risks. FDA: risks of compounded drugs

FDA has specifically warned about unsuitable food-grade NAD+ ingredients being used in sterile IV products and reported reactions consistent with excessive endotoxins. This alert is not an accusation against the providers listed here. It is a reason to ask who dispenses the product and how quality and sterility are assured. FDA: ingredients suitable for sterile compounding The NAD+ injection side-effects guide separates those reports from the small IV evidence.

The plans in this comparison are marketed through a clinical assessment and prescription process. “Rx” means prescription. Paying for an assessment or choosing a plan does not guarantee a prescription, and a platform's general state coverage does not guarantee access to every product.

Before starting intake, check the clinician process, medication-specific state availability, the dispensing pharmacy, and whether payment is collected before or after approval. For example, Luvo's public pages give conflicting signals about when the first charge occurs. That is a purchasing detail to resolve before submitting a paid order.

The answer changes when the headline is an introductory month, a weekly annual-plan average or a full treatment term. Our NAD+ cost guide keeps those amounts separate and shows the source behind each record. Exact quantity and extra fees remain questions for the final quote.

Use the specific route or molecule comparison that matches the decision. Each page keeps the product, population and evidence boundary visible before moving to a provider plan.